A 13-Year National Monitoring Study to Assess Narcotic Prescriptions and Indications (2007-2019).
Journal
Drug safety
ISSN: 1179-1942
Titre abrégé: Drug Saf
Pays: New Zealand
ID NLM: 9002928
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
accepted:
21
09
2021
pubmed:
30
10
2021
medline:
22
4
2022
entrez:
29
10
2021
Statut:
ppublish
Résumé
Analgesics are among the most widely used drugs worldwide. This study describes the population treated with narcotic analgesics, their therapeutic indications and how the data have evolved over a decade. A cross-sectional, national, multicentre survey study was conducted that included surveys taken every year from 2007 to 2019 in a national sample of 1500 randomly selected dispensing pharmacies. The mean age of patients, mostly women (around 60%), remained stable over the study period (63.2 ± 17.1 years in 2007, 68.2 ± 17.2 years in 2019). The proportion of patients treated for more than 3 months increased from 2007 to 2019. Most prescriptions involved morphine, oxycodone and fentanyl (98.5% of all prescriptions in 2019). Morphine prescriptions dropped dramatically from 49.6% (2007) to 32.3% (2019) of the total narcotic analgesics. Fentanyl prescriptions varied from 40.1% in 2007 to 32.2% in 2019. Prescriptions of oxycodone, regardless of the indication, increased steadily from 2007, from 8.3 to 34% in 2019, becoming the most prescribed narcotic analgesic for the first time since the beginning of the survey. This study demonstrates how narcotic opioids are prescribed, thanks to the active participation of health professionals, and confirms the striking increase in the prescription of oxycodone.
Identifiants
pubmed: 34714529
doi: 10.1007/s40264-021-01124-5
pii: 10.1007/s40264-021-01124-5
doi:
Substances chimiques
Analgesics, Opioid
0
Narcotics
0
Morphine
76I7G6D29C
Oxycodone
CD35PMG570
Fentanyl
UF599785JZ
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
37-44Investigateurs
Nathalie Fouilhé
(N)
Alexandra Boucher
(A)
Stéphanie Pain
(S)
Samira Djezzar
(S)
Hélène Peyrière
(H)
Marie Gérardin
(M)
Christine Fournier-Choma
(C)
Valérie Gibaja
(V)
Reynald Boisselier
(R)
Anne-Sylvie Caous
(AS)
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Chang HY, Daubresse M, Kruszewski SP, Alexander GC. Prevalence and treatment of pain in EDs in the United States, 2000 to 2010. Am J Emerg Med. 2014;32:421–31. https://doi.org/10.1016/j.ajem.2014.01.015 .
doi: 10.1016/j.ajem.2014.01.015
pubmed: 24560834
Christie D. “The analgesic abuse syndrome”: an epidemiological perspective. Int J Epidemiol. 1978;7:139–43. https://doi.org/10.1093/ije/7.2.139 .
doi: 10.1093/ije/7.2.139
pubmed: 681060
Lalic S, Ilomaki J, Bell JS, Korhonen MJ, Gisev N. Prevalence and incidence of prescription opioid analgesic use in Australia. Br J Clin Pharmacol. 2019;85:202–15. https://doi.org/10.1111/bcp.13792 .
doi: 10.1111/bcp.13792
pubmed: 30338545
Daveluy A, Micallef J, Sanchez-Pena P, Miremont-Salamé G, Lassalle R, Lacueille C, et al. Ten-year trend of opioid and non-opioid analgesic use in the French adult population. Br J Clin Pharmacol. 2021;87:555–64. https://doi.org/10.1111/bcp.14415 .
doi: 10.1111/bcp.14415
pubmed: 32496599
Hider-Mlynarz K, Cavalié P, Maison P. Trends in analgesic consumption in France over the last 10 years and comparison of patterns across Europe. Br J Clin Pharmacol. 2018;84:1324–34. https://doi.org/10.1111/bcp.13564 .
doi: 10.1111/bcp.13564
pubmed: 29514410
pmcid: 5980622
Dhalla IA, Mamdani MM, Sivilotti ML, Kopp A, Qureshi O, Juurlink DN. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. CMAJ. 2009;181:891–6. https://doi.org/10.1503/cmaj.090784 .
doi: 10.1503/cmaj.090784
pubmed: 19969578
pmcid: 2789126
Hauser W, Schug S, Furlan AD. The opioid epidemic and national guidelines for opioid therapy for chronic noncancer pain: a perspective from different continents. Pain Rep. 2017;2: e599. https://doi.org/10.1097/pr9.0000000000000599 .
doi: 10.1097/pr9.0000000000000599
pubmed: 29392214
pmcid: 5741305
Hernandez SH, Nelson LS. Prescription drug abuse: insight into the epidemic. Clin Pharmacol Ther. 2010;88:307–17. https://doi.org/10.1038/clpt.2010.154 .
doi: 10.1038/clpt.2010.154
pubmed: 20686478
Morley KI, Ferris JA, Winstock AR, Lynskey MT. Polysubstance use and misuse or abuse of prescription opioid analgesics: a multi-level analysis of international data. Pain. 2017;158:1138–44. https://doi.org/10.1097/j.pain.0000000000000892 .
doi: 10.1097/j.pain.0000000000000892
pubmed: 28267061
Wegrzyn EL, Chaghtai AM, Argoff CE, Fudin J. The CDC opioid guideline: proponent interpretation has led to misinformation. Clin Pharmacol Ther. 2018;103:950–3. https://doi.org/10.1002/cpt.1062 .
doi: 10.1002/cpt.1062
pubmed: 29608033
Soeiro T, Pradel V, Lapeyre Mestre M, Micallef J. Evolution of doctor shopping for oxycodone in the 67 million inhabitants in France as a proxy for potential misuse or abuse. Pain. 2021;162:770–7. https://doi.org/10.1097/j.pain.0000000000002093 .
doi: 10.1097/j.pain.0000000000002093
pubmed: 33021567
van Amsterdam J, Pierce M, van den Brink W. Is Europe facing an emerging opioid crisis comparable to the U.S.? Ther Drug Monit. 2021;43:42–51. https://doi.org/10.1097/ftd.0000000000000789 .
doi: 10.1097/ftd.0000000000000789
pubmed: 32649487
Baumevieille M, Daveluy A, Maurain C, Bégaud B, Haramburu F. Medicines submitted to narcotics regulations in France, 1992–2007. Fundam Clin Pharmacol. 2009;23:345–9. https://doi.org/10.1111/j.1472-8206.2009.00678.x .
doi: 10.1111/j.1472-8206.2009.00678.x
pubmed: 19453761
Baumevieille M, Perri-Plande J, Miremont-Salame G, Daveluy A, Haramburu F. From psychoactive medicines to addictovigilance in French Public Health Code (1990–2017). Therapie. 2019;74:375–82. https://doi.org/10.1016/j.therap.2018.07.007 .
doi: 10.1016/j.therap.2018.07.007
pubmed: 30193805
Daveluy A, Sauvaget L, Bastien A, Lapeyre-Mestre M, Collin C, Richard N, et al. Tamper-resistant prescription forms for narcotics in France: Should we generalize them? Fundam Clin Pharmacol. 2018;32:571–7. https://doi.org/10.1111/fcp.12368 .
doi: 10.1111/fcp.12368
pubmed: 29582450
Peyrière H, Nogue E, Eiden C, Frauger E, Charra M, Picot MC. Evidence of slow-release morphine sulfate abuse and diversion: epidemiological approaches in a French administrative area. Fundam Clin Pharmacol. 2016;30:466–75. https://doi.org/10.1111/fcp.12210 .
doi: 10.1111/fcp.12210
pubmed: 27315486
Pauly V, Pradel V, Pourcel L, Nordmann S, Frauger E, Lapeyre-Mestre M, et al. Estimated magnitude of diversion and abuse of opioids relative to benzodiazepines in France. Drug Alcohol Depend. 2012;126:13–20. https://doi.org/10.1016/j.drugalcdep.2012.03.009 .
doi: 10.1016/j.drugalcdep.2012.03.009
pubmed: 22475815
Micallef J, Jouanjus E, Mallaret M, Lapeyre MM. Safety signal detection by the French Addictovigilance Network: innovative methods of investigation, examples and usefulness for public health. Therapie. 2019;74:579–90. https://doi.org/10.1016/j.therap.2019.09.005 .
doi: 10.1016/j.therap.2019.09.005
pubmed: 31694770
Dupouy J, Palmaro A, Fatseas M, Auriacombe M, Micallef J, Oustric S, et al. Mortality associated with time in and out of buprenorphine treatment in French office-based general practice: a 7-Year Cohort Study. Ann Fam Med. 2017;15:355–8. https://doi.org/10.1370/afm.2098 .
doi: 10.1370/afm.2098
pubmed: 28694272
pmcid: 5505455
Ponte C, Lepelley M, Boucherie Q, Mallaret M, Lapeyre Mestre M, Pradel V, et al. Doctor shopping of opioid analgesics relative to benzodiazepines: a pharmacoepidemiological study among 11.7 million inhabitants in the French countries. Drug Alcohol Depend. 2018;187:88–94. https://doi.org/10.1016/j.drugalcdep.2018.01.036 .
doi: 10.1016/j.drugalcdep.2018.01.036
pubmed: 29649695
Ministrère des solidarités et de la santé. Base de données publique des médicaments. 2020. http://base-donnees-publique.medicaments.gouv.fr/ . Accessed 30 July 2021.
Delorme J, Chenaf C, Bertin C, Riquelme M, Eschalier A, Ardid D, et al. Chronic pain opioid-maintained patients receive less analgesic opioid prescriptions. Front Psychiatry. 2018;9:335. https://doi.org/10.3389/fpsyt.2018.00335 .
doi: 10.3389/fpsyt.2018.00335
pubmed: 30083113
pmcid: 6065119
Haute Autorité de Santé (HAS). Avis de la transparence: Durogesic, February 2008. https://www.has-sante.fr . Accessed 30 July 2021.
Haute Autorité de Santé (HAS). Avis de la transparence: Oxycontin®, Oxynorm®, Oxynormoro®, September 2012. https://www.has-sante.fr . Accessed 30 July 2021.
Trouvin AP, Chenaf C, Riquelme M, Curis E, Nicolis I, Javier RM, et al. Opioid epidemic: does rheumatological practice favors risk for patients? National survey on rheumatologists’ opioid prescriptions and compliance to guidelines for strong opioid prescription. Jt Bone Spine. 2021;88: 105046. https://doi.org/10.1016/j.jbspin.2020.06.019 .
doi: 10.1016/j.jbspin.2020.06.019
Muller AE, Clausen T, Sjogren P, Odsbu I, Skurtveit S. Prescribed opioid analgesic use developments in three Nordic countries, 2006–2017. Scand J Pain. 2019;19:345–53. https://doi.org/10.1515/sjpain-2018-0307 .
doi: 10.1515/sjpain-2018-0307
pubmed: 30677000
Gisev N, Pearson SA, Blanch B, Larance B, Dobbins T, Larney S, et al. Initiation of strong prescription opioids in Australia: cohort characteristics and factors associated with the type of opioid initiated. Br J Clin Pharmacol. 2016;82:1123–33. https://doi.org/10.1111/bcp.13026 .
doi: 10.1111/bcp.13026
pubmed: 27260937
pmcid: 5137837
Ayoo K, Mikhaeil J, Huang A, Wasowicz M. The opioid crisis in North America: facts and future lessons for Europe. Anaesthesiol Intensive Ther. 2020. https://doi.org/10.5114/ait.2020.94756 .
doi: 10.5114/ait.2020.94756
pubmed: 32702941
Jones MR, Viswanath O, Peck J, Kaye AD, Gill JS, Simopoulos TT. A brief history of the opioid epidemic and strategies for pain medicine. Pain Ther. 2018;7:13–21. https://doi.org/10.1007/s40122-018-0097-6 .
doi: 10.1007/s40122-018-0097-6
pubmed: 29691801
pmcid: 5993682
Bigal LM, Bibeau K, Dumbar S. Patterns in opioid prescription in the United States by region and prescribers over a 4-year period. J Opioid Manag. 2019;15:499–506. https://doi.org/10.5055/jom.2019.0541 .
doi: 10.5055/jom.2019.0541
pubmed: 31850512
Ojanpera I, Kriikku P, Vuori E. Fatal toxicity index of medicinal drugs based on a comprehensive toxicology database. Int J Legal Med. 2016;130:1209–16. https://doi.org/10.1007/s00414-016-1358-8 .
doi: 10.1007/s00414-016-1358-8
pubmed: 26987318
Cicero TJ, Ellis MS, Kasper ZA. A tale of 2 ADFs: differences in the effectiveness of abuse-deterrent formulations of oxymorphone and oxycodone extended-release drugs. Pain. 2016;157:1232–8. https://doi.org/10.1097/j.pain.0000000000000511 .
doi: 10.1097/j.pain.0000000000000511
pubmed: 27186712
Nordmann S, Pradel V, Lapeyre-Mestre M, Frauger E, Pauly V, Thirion X, et al. Doctor shopping reveals geographical variations in opioid abuse. Pain Physician. 2013;16:89–100.
pubmed: 23340537
Frauger E, Pochard L, Boucherie Q, Giocanti A, Chevallier C, Daveluy A, et al. Surveillance system on drug abuse: Interest of the French national OPPIDUM program of French addictovigilance network. Therapie. 2017;72:491–501. https://doi.org/10.1016/j.therap.2017.01.010 .
doi: 10.1016/j.therap.2017.01.010
pubmed: 28343650
Micallef J, Pauly V, Ponte C, Giocanti A, Pochard L, Frauger E, et al. French pharmacosurveillance of opioid analgesics: results of disproportionality analysis from OPPIDUM (Observation of psychoactive substance consumption). Fundam Clin Pharmacol. 2018;32:188–97.
doi: 10.1111/fcp.12382
Aknouche F, Guibert E, Tessier A, Alvarez JC, Lemaire-Hurtel AS, Kintz P. Unusual deaths in France: about 3 cases involving oxycodone. Toxicol Anal Clin. 2015;27:52–6.
Jouanjus E, Guernec G, Lapeyre-Mestre M, French AN. Medical prescriptions falsified by the patients: a 12-year national monitoring to assess prescription drug diversion. Fundam Clin Pharmacol. 2018;32:306–22. https://doi.org/10.1111/fcp.12356 .
doi: 10.1111/fcp.12356
pubmed: 29436015
Tournebize J, Gibaja V, Frauger E, Authier N, Seyer D, Perri-Plande J, et al. French trends in the misuse of Fentanyl: From 2010 to 2015. Therapie. 2020;75:491–502. https://doi.org/10.1016/j.therap.2019.11.002 .
doi: 10.1016/j.therap.2019.11.002
pubmed: 31826806
French Addictovigilance Network. Misuses and risks of transmucosal fentanyl. 2020: http://www.addictovigilance.fr/IMG/pdf/bulletin_addictovigilance_ftm_vf_site.pdf . Accessed 30 July 2021.
Gentile G, Jego M, Spadari M, Griffiths K, Jouanjus E, Micallef J. Identification and tracking of Addictovigilance signals in general practice: which interactions between the general practitioners and the French Addictovigilance Network? Fundam Clin Pharmacol. 2018;32:643–51. https://doi.org/10.1111/fcp.12401 .
doi: 10.1111/fcp.12401
pubmed: 30003596
Société française d'évaluation et de traitement de la douleur (SFETD). Utilisation des opioïdes forts dans la douleur chronique non cancéreuse chez l’adulte. 2016. https://www.sfetd-douleur.org/sites/default/files/u3349/recommandations/recos_opioides_forts_sfetd_version_longue.compressed.pdf . Accessed 30 July 2021.
Henry SG, Bell RA, Fenton JJ, Kravitz RL. Communication about chronic pain and opioids in primary care: impact on patient and physician visit experience. Pain. 2018;159:371–9. https://doi.org/10.1097/j.pain.0000000000001098 .
doi: 10.1097/j.pain.0000000000001098
pubmed: 29112009
pmcid: 5934342
Driot D, Jouanjus E, Oustric S, Dupouy J, Lapeyre-Mestre M. Patterns of gabapentin and pregabalin use and misuse: Results of a population-based cohort study in France. Br J Clin Pharmacol. 2019;85:1260–9. https://doi.org/10.1111/bcp.13892 .
doi: 10.1111/bcp.13892
pubmed: 30737829
pmcid: 6533441
Hägg S, Jonsson AK, Ahlner J. Current evidence on abuse and misuse of gabapentinoids. Drug Saf. 2020;43:1235–54. https://doi.org/10.1007/s40264-020-00985-6 .
doi: 10.1007/s40264-020-00985-6
pubmed: 32857333
pmcid: 7686181